This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Bromperidol is a first-generation butyrophenone antipsychotic used in the treatment of schizophrenia and other psychotic manifestations.
- Generic Name
- Bromperidol
- DrugBank Accession Number
- DB12401
- Background
Bromperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Bromperidol (DB12401)
- Weight
- Average: 420.322
Monoisotopic: 419.08962 - Chemical Formula
- C21H23BrFNO2
- Synonyms
- Bromperidol
- External IDs
- R 11,333
- R-11333
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Schizophrenic psychoses •••••••••••• ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Bromperidol is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Bromperidol. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Bromperidol. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Bromperidol. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Bromperidol. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- N05AD06 — Bromperidol
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbonyl compounds
- Direct Parent
- Alkyl-phenylketones
- Alternative Parents
- Phenylpiperidines / Phenylbutylamines / Butyrophenones / Aryl alkyl ketones / Benzoyl derivatives / Aralkylamines / Fluorobenzenes / Bromobenzenes / Aryl bromides / Aryl fluorides show 9 more
- Substituents
- Alcohol / Alkyl-phenylketone / Amine / Aralkylamine / Aromatic heteromonocyclic compound / Aryl alkyl ketone / Aryl bromide / Aryl fluoride / Aryl halide / Azacycle show 23 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- LYH6F7I22E
- CAS number
- 10457-90-6
- InChI Key
- RKLNONIVDFXQRX-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
- IUPAC Name
- 4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
- SMILES
- OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1
References
- General References
- AIFA Product Information: Impromen (bromperidol) for oral use [Link]
- External Links
- PubChem Compound
- 2448
- PubChem Substance
- 347828647
- ChemSpider
- 2354
- BindingDB
- 81484
- 19777
- ChEBI
- 31305
- ChEMBL
- CHEMBL28218
- ZINC
- ZINC000000601270
- Wikipedia
- Bromperidol
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Completed Treatment Schizoaffective Disorders / Schizophrenia / Schizophrenia and Disorders With Psychotic Features 1 somestatus stop reason just information to hide 3 Terminated Treatment Anxiety Disorders / Dementia / Depression / Psychosomatic Disorders / Schizophrenia 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral 2 mg Solution / drops Oral 10 MG/ML Solution / drops Oral 2 MG/ML Tablet Oral 1 MG Tablet Oral 10 MG Tablet Oral 5 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00723 mg/mL ALOGPS logP 3.78 ALOGPS logP 3.83 Chemaxon logS -4.8 ALOGPS pKa (Strongest Acidic) 13.97 Chemaxon pKa (Strongest Basic) 8.07 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 40.54 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 105.41 m3·mol-1 Chemaxon Polarizability 41.37 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 189.04526 predictedDeepCCS 1.0 (2019) [M+H]+ 191.52464 predictedDeepCCS 1.0 (2019) [M+Na]+ 199.09874 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 22:14 / Updated at May 27, 2021 02:57